Advertisement Parexel launches perceptive MyTrials Data-Driven Monitoring solution - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Parexel launches perceptive MyTrials Data-Driven Monitoring solution

Parexel International, a global biopharmaceutical services organization, has announced the launch of its Perceptive MyTrials Data-Driven Monitoring solution.

Developed by PAREXEL Informatics, it is a key component of the Perceptive MyTrials eClinical platform, an integrated suite of applications for managing clinical trials.

On-site monitoring is a critical aspect of trial management, with the primary function of identifying and mitigating patient safety or data quality risks at investigative sites.

The US Food and Drug Administration (FDA) and other regulatory bodies have issued guidance to assist sponsors in developing risk-based monitoring strategies that enhance patient protection and improve trial data quality through more effective study oversight. They have encouraged greater use of centralized monitoring methods to evaluate clinical trial conduct and progress.

PAREXEL’s new data-driven monitoring solution provides an innovative approach to centralized risk-based monitoring. The technology captures, consolidates and organizes clinical information in real-time from disparate sources.

As a result, drug developers can accurately identify study risks and rapidly determine what type of intervention may be required. Monitoring focused on specific risk offers the potential to enhance patient safety, reduce costs and promote regulatory compliance.

PAREXEL Informatics president Xavier Flinois said that Perceptive MyTrials Data-Driven Monitoring uses clinical data to guide monitoring activities as an alternative to periodically scheduled monitoring visits, which can be time-consuming, costly and inefficient.

"Greater insight into study data allows for a more precise determination of when on-site monitoring visits need to occur and what activities should be undertaken during those visits. This can make clinical trial participation safer for patients while offering cost efficiencies for sponsors," Flinois added.